Actinogen Medical Ltd has released a press release.
R&D Rebate
Filed with ASX ·
On 6ix: 6ix.com/news/randd-rebate
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- Update on the Biofuel Research Program
- Trials recommence on antibiotic project
- Suspension of ACWN and ACWO 1/08/13
- Supplementary prospectus - withdrawal of offer
- Supplementary prospectus and amended timetable
Later from Actinogen Medical
- Appendix 4D & Half Year Report
- Launch of XanADu Phase II Clinical Trial
- US FDA Feedback Enhances Alzheimers Study
- US Patent Granted-Further Extends Xanamem Protection
- Landmark Research on Excess Cortisol & Alzheimers Disease
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical